Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
After all these years, why has patient safety not improved? In late 1999, the US Institute of Medicine’s report “To Err is Human: Building a…
This systematic review and meta-analysis evaluates the frequency of reactions to direct penicillin challenges in individuals with penicillin allergy labels across diverse patient populations.
In this Review, Chen and Kim explore the exciting journey of discovering small and long non-coding RNAs. They also explain the current understanding as to…
The card brand uses a new form of generative AI that improves data sourcing, making human involvement less necessary.
What are the early signs of multiple sclerosis, a disease that affects your central nervous system? Symptoms like blurred vision, numbness, weakness and dizziness that…
Sizeable case series gives evidentiary boost to spine stereotactic radiosurgery for symptomatic vertebral hemangioma with epidural extension
Only a third of scientific journals on PubMed post conflicts of interest
In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were…
This study aims to characterize the individual-level agreement of polygenic risk scores for coronary heart disease that perform similarly at the population level.
Scientists looked into the efficacy of an app that claims to help people lucid dream — and found that it tripled their awareness of their…